Skip to main content
PMC home page
Clinical Cardiology logoLink to Clinical Cardiology
. 2009 Feb 3;21(2):103–108. doi: 10.1002/clc.4960210208

Factors determining angiotensin‐converting enzyme inhibitor underutilization in heart failure in a community setting

Edward F Philbin 1,✉
PMCID: PMC6656106  PMID: 9491949

Abstract

Background: Angiotensin‐converting enzyme (ACE) inhibitors were underprescribed for patients with congestive heart failure (CHF) treated in the community setting in the early 1990s despite convincing evidence of benefit.

Hypothesis: We postulated that (1) the prevalence of ACE inhibitor use has increased, and (2) prescribing biases have narrowed, as community physicians have gained additional clinical experience with these drugs for treatment of CHF.

Methods: We examined rates of ACE inhibitor use among 1, 150 patients with CHF hospitalized at 10 community hospitals in 1995, evaluated determinants of ACE inhibitor prescription, and compared the results with survey data gathered among similar patients during 1992.

Results: Compared with 1992, ACE inhibitor use prior to hospital admission was increased among all patients (42 vs. 33%, p < 0.001) and the subset with a history of CHF (53 vs. 39%, p< 0.0005). Angiotensin‐converting enzyme inhibitor prescription at hospital discharge also increased among all survivors (64 vs. 51%, p < 0.00005) and the subset eligible for ACE inhibitor treatment based on clinical trial criteria (77 vs. 66%, p = 0.04). Multivariate analysis suggested no change in the prescribing biases previously observed; ACE inhibitor use was related to lower ejection fraction, lower serum creatinine, documentation of left ventricular systolic function, younger patient age, prescription of any diuretic drug, and nonprescription of alternate vasodilators and calcium blockers. In multivariate analyses, physician specialty did not predict ACE inhibitor use.

Conclusions: Angiotensin‐converting enzyme inhibitor use among patients with CHF is increasing but remains below the 80‐90% rates of drug tolerance documented in randomized clinical trials. This discrepancy is partially explained by the prevalence of renal impairment and “diastolic” heart failure in the community setting. However, age bias, use of alternative vasodilators, and substandard quality of care may also play a role.

Keywords: congestive heart failure, angiotensin‐converting enzyme inhibitors, diastole

Full Text

The Full Text of this article is available as a PDF (632.5 KB).

References

  • 1. Captopril Multicenter Research Group : A placebo‐controlled trial of refractory chronic congestive heart failure. J Am Coll Cardiol 1983; 2: 755–763 [DOI] [PubMed] [Google Scholar]
  • 2. Packer M, Lee WH, Yushak M, Medina N: Comparison of captopril and enalapril in patients with severe chronic heart failure. N Engl J Med 1986; 315: 847–853 [DOI] [PubMed] [Google Scholar]
  • 3. Kjekshus J, Swedberg K: Tolerability of enalapril in congestive heart failure. Am J Cardiol 1988; 62: 67A–72A [DOI] [PubMed] [Google Scholar]
  • 4. The CONSENSUS Trial Study Group : Effects of enalapril on mortality in severe congestive heart failure: Results of the Cooperative North Scandinavian Enalapril Survival Study. N Engl J Med 1987; 316: 1429–1435 [DOI] [PubMed] [Google Scholar]
  • 5. The SOLVD Investigators : Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325: 293–302 [DOI] [PubMed] [Google Scholar]
  • 6. Rogers WJ, Johnstone DE, Yusuf S, Weiner DH, Gallagher P, Bittner VA, Ahn S, Schron E, Shumaker SA, Sheffield LT: Quality of life among 5,025 patients with left ventricular dysfunction randomized between placebo and enalapril: The Studies of Left Ventricular Dysfunction. J Am Coll Cardiol 1994; 23: 393–400 [DOI] [PubMed] [Google Scholar]
  • 7. Cohn JN, Johnson G, Zieshe S, Cobb F, Francis G, Tritsani F, Smith R, Dunkman WB, Loeb H, Wong M, Bhat G, Goldman S, Fletcher RD, Doherty J, Hughes CV, Carson P, Cintron G, Shabetai R, Haakenson C: A comparison of enalapril with hydralazine‐isosorbide in the treatment of chronic congestive heart failure. N Engl J Med 1991; 325: 303–310 [DOI] [PubMed] [Google Scholar]
  • 8. Pfeffer MA, Braunwald E, Moyé LA, Basta L, Brown EJ, Cuddy TE, Davis BR, Geltman EM, Goldman S, Flaker GC, Klein M, Lamas GA, Packer M, Rouleau J, Rouleau JL, Rutherford J, Wert‐heimer JH, Hawkins CM: Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1992; 327: 669–677 [DOI] [PubMed] [Google Scholar]
  • 9. Paul SD, Kuntz KM, Eagle KA, Weinstein NC: Costs and effectiveness of angiotensin converting enzyme inhibition in patients with congestive heart failure. Arch Intern Med 1994; 154: 1143–1149 [PubMed] [Google Scholar]
  • 10. Konstam MA, Dracup K, Bottoroff MB, Brooks NH, Dacey RA, Dunbar SB, Jackson AB, Jessup M, Johnson JC, Jones RH, Luchi RJ, Massie BM, Pitt B, Rose EA, Rubin LJ, Wright RF: Quick Reference Guide for Clinicians No. 11: Heart Failure: Management of Patients with Left Ventricular Systolic Dysfunction. Rockville, MD: Agency for Health Care Policy and Research, Public‐Health Service, United States Department of Health and Human Services, AHCPR Publication No. 94‐0613, 1994. [Google Scholar]
  • 11. Johnstone DE, Abdulla A, Arnold JMO, Bernstein V, Bourassa M, Brophy J, Davies R, Gardner M, Hoeschen R, Mickleborough L, Moe G, Montague T, Paquet M, Rouleau JL, Yusuf S: Diagnosis and management of heart failure. Can J Cardiol 1994; 10: 613–631 [PubMed] [Google Scholar]
  • 12. Rajfer SI: Perspective of the pharmaceutical industry on the development of new drugs for heart failure. J Am Coll Cardiol 1993; 22 (suppl A): 198A–200A [DOI] [PubMed] [Google Scholar]
  • 13. O'Connell JB, Bristow MR: Economic impact of heart failure in the United States: Time for a different approach. J Heart Lung Transplant 1994; 13: S107–112 [PubMed] [Google Scholar]
  • 14. Philbin EF, Andreou C, Rocco TA, Lynch LJ, Baker SL: Patterns of angiotensin‐converting enzyme inhibitor use in congestive heart failure in two community hospitals. Am J Cardiol 1996; 77: 832–838 [DOI] [PubMed] [Google Scholar]
  • 15. Stafford RS, Saglam D, Blumenthal D: Low rates of angiotensin‐converting enzyme inhibitor use in congestive heart failure (abstr). Circulation 1996; 94 (suppl I): I–194 [PubMed] [Google Scholar]
  • 16. Shah N, Edep M, Massie BM: Differences between cardiologists and heart failure specialists in the management of congestive heart failure (abstr). Circulation 1995; 92 (suppl I): I–666 [DOI] [PubMed] [Google Scholar]
  • 17. Philbin EF, Lynch LJ, Rocco TA, Lindenmuth NW, Ulrich K, McCall M, Roerden JB, Jenkins P: Does quality improvement work? The Management to Improve Survival in Congestive Heart Failure (MISCHF) Study. Jt Comm J Qual Improv 1996; 22: 721–733 [DOI] [PubMed] [Google Scholar]
  • 18. 3M Health Information Services, U.S. Health Care Financing Administration : Diagnosis Related Groups Definitions Manual. Wallingford, Conn.: 3M Health Information Services, 1993. [Google Scholar]
  • 19. 3M Health Information Services, New York State Department of Health Division of Health Care Financing : All Patient Diagnosis Related Groups Definitions Manual. Wallingford, Conn.: 3M Health Information Services, 1993. [Google Scholar]
  • 20. Mohan P, Hii JT, Wuttke RD, Esterman AJ, Hollington P, Horowitz JD: Acute heart failure: Determinants of outcome. Int J Cardiol 1991; 32: 365–376 [DOI] [PubMed] [Google Scholar]
  • 21. Cohn JN, Johnson GR, Shabetai R, Loeb H, Tristani F, Rector T, Smith R, Fletcher R: Ejection fraction, peak exercise oxygen consumption, cardiothoracic ratio, ventricular arrhythmias and plasma norepinephrine as determinants of prognosis in heart failure. Circulation 1993; 87 (suppl VI): VI‐5–VI‐16 [PubMed] [Google Scholar]
  • 22. Franciosa JA: Why patients with heart failure die: Hemodynamic and functional determinants of survival. Circulation 1987; 75 (suppl IV): IV‐20–IV‐27 [PubMed] [Google Scholar]
  • 23. Gradman AH, Deedwania PC: Predictors of mortality in patients with heart failure. Cardiol Clinics 1994; 12 (1): 25–35 [PubMed] [Google Scholar]
  • 24. Charlson ME, Pompei P, Ales KL, MacKenzie CR: A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chron Dis 1987; 40: 373–383 [DOI] [PubMed] [Google Scholar]
  • 25. Bonow RO, Udelson JE: Left ventricular diastolic dysfunction as a cause of congestive heart failure: Mechanisms and management. Ann Intern Med 1992; 117: 502–510 [DOI] [PubMed] [Google Scholar]
  • 26. Vasan RS, Benjamin EJ, Levy D: Prevalence, clinical features and prognosis of diastolic heart failure. J Am Coll Cardiol 1995; 26: 1565–1574 [DOI] [PubMed] [Google Scholar]
  • 27. Philbin EF, Rocco TA: The utility of angiotensin‐converting enzyme inhibitors in heart failure with preserved left ventricular systolic function. Am Heart J 1997; 134: 188–195 [DOI] [PubMed] [Google Scholar]
  • 28. Suki WN: Renal hemodynamic consequences of angiotensin‐converting enzyme inhibition in congestive heart failure. Arch Intern Med 1989; 149: 669–673 [PubMed] [Google Scholar]
  • 29. Oster JR, Materson BJ: Renal and electrolyte complications of congestive heart failure and effects of therapy with angiotensin‐converting enzyme inhibitors. Arch Intern Med 1992; 152: 704–710 [PubMed] [Google Scholar]
  • 30. Cohn JN, Archibald DG, Ziesche S, Franciosa JA, Harston WE, Tritsani FE, Dunkman WB, Jacobs W, Francis GS, Flohr KH, Goldman S, Cobb FR, Shah PM, Saunders R, Fletcher RD, Loeb HS, Hughes VC, Baker B: Effect of vasodilator therapy on mortality in chronic congestive heart failure: Results of a Veterans Administration Cooperative Study. N Engl J Med 1986; 314: 1547–1552 [DOI] [PubMed] [Google Scholar]
  • 31. Packer M, Kessler PD, Lee WH: Calcium‐channel blockade in the management of severe chronic congestive heart failure: A bridge too far. Circulation 1987; 75 (suppl V): V56–V64 [PubMed] [Google Scholar]
  • 32. Pilote L, Miller DP, Califf RM, Rao JS, Weaver WD, Topol EJ: Determinants of the use of coronary angiography and revascularization after thrombolysis for acute myocardial infarction. N Engl J Med 1996; 335: 1198–1205 [DOI] [PubMed] [Google Scholar]
  • 33. Williams JF, Bristow MR, Fowler MB, Francis GS, Garson A, Gersh BJ, Hammer DF, Hlatky MA, Leier CV, Packer M, Pitt B, Ullyot DJ, Wexler LF, Winters WL: Guidelines for the evaluation and management of heart failure. Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Evaluation and Management of Heart Failure). Circulation 1995; 92: 2764–2784 [DOI] [PubMed] [Google Scholar]
  • 34. Blumenthal D: Quality of health care. Part 1: Quality of care ‐ what is it? N Engl J Med 1996; 335: 891–893 [DOI] [PubMed] [Google Scholar]
  • 35. West JA, Miller NH, Parker KM, Senneca D, Ghandour G, Clark M, Greenwald G, Heller RS, Fowler MB, DeBusk RF: A comprehensive management system for heart failure improves clinical outcomes and reduces medical resource utilization. Am J Cardiol 1997; 79: 58–63 [DOI] [PubMed] [Google Scholar]

Articles from Clinical Cardiology are provided here courtesy of Wiley

RESOURCES